We are live on ! Find out more

938 hedge funds and large institutions have $22.2B invested in ResMed in 2026 Q1 according to their latest regulatory filings, with 105 funds opening new positions, 360 increasing their positions, 319 reducing their positions, and 97 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more funds holding in top 10

Funds holding in top 10: 58 (+3)

13% more repeat investments, than reductions

Existing positions increased: 360 | Existing positions reduced: 319

8% more first-time investments, than exits

New positions opened: 105 | Existing positions closed: 97

0.53% more ownership

Funds ownership: 66.49%67.02% (+0.53%)

1% less funds holding

Funds holding: 945938 (-7)

5% less capital invested

Capital invested by funds: $23.4B → $22.2B (-$1.16B)

71% less call options, than puts

Call options by funds: $58.1M | Put options by funds: $201M

Holders
938
Holders Change
-7
Holders Change %
-0.74%
% of All Funds
11.54%
Holding in Top 10
8
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+60%
% of All Funds
0.1%
New
105
Increased
360
Reduced
319
Closed
97
Calls
$58.1M
Puts
$201M
Net Calls
-$143M
Net Calls Change
+$79M

RMD Hedge Fund Activity: Q1 2026 in Review

938 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q1 2026, worth a combined $22.2B — down 5% from $23.4B a quarter earlier.

Buyers outnumbered sellers: 105 funds opened new RMD positions and 97 closed out — a net gain of 8 holders — while 360 added to existing stakes and 319 trimmed.

The largest buyer was Amundi, adding an estimated $146M. The largest seller was T. Rowe Price Associates, cutting an estimated $74.2M.

  • 938 institutional investors held ResMed (RMD) as of Q1 2026, down from 945 in Q4 2025.
  • Funds reported $22.2B of ResMed stock for Q1 2026, down 5% quarter-over-quarter.
  • 105 funds opened new ResMed positions in Q1 2026 and 97 closed out, a net change of +8 holders.
  • The largest ResMed buyer in Q1 2026 was Amundi, an estimated $146M added.
  • The largest ResMed seller in Q1 2026 was T. Rowe Price Associates, an estimated $74.2M sold.

Based on aggregated 13F filings for Q1 2026.